Home
Search
Study Topics
Glossary
|
Descriptive Information Fields | |||||
---|---|---|---|---|---|
Brief Title † | Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma | ||||
Official Title † | Treatment of Patients With Metastatic Melanoma Using Cloned Lymphocytes Following the Administration of a Nonmyeloablative But Lymphocyte Depleting Regimen | ||||
Brief Summary | RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Treating a patient's white blood cells with interleukin-2 may stimulate them to kill tumor cells. PURPOSE: This phase II trial is studying how well giving chemotherapy together with biological therapy works in treating patients with metastatic melanoma that has not responded to previous therapy. |
||||
Detailed Description | OBJECTIVES:
OUTLINE: This is a dose-escalation study of interleukin-2 (IL-2), cyclophosphamide, and fludarabine. Patients are stratified according to route of administration of cloned lymphocytes (IV vs intra-arterial). Phase I (Closed to accrual effective 07/24/2001)
All patients receive activated lymphocytes IV or intra-arterially over 20-30 minutes on day 0*. Patients with a predominant site of disease with an identifiable vascular supply to tumor(s) receive cells via intra-arterial infusion. Beginning 1-2 days after completion of lymphocyte infusion, some patients receive filgrastim (G-CSF) subcutaneously once daily until blood counts recover. NOTE: *Day 0 is 1-4 days after completion of fludarabine administration.
NOTE: **Immunization occurs on the same day as lymphocyte infusion Phase II
NOTE: ***Patients ineligible to receive high-dose IL-2 due to the presence of cardiovascular or respiratory system illness may receive low-dose IL-2 SC daily on days 0-4, 7-11, 14-18, 21-25, 28-32, and 35-39. Patients are followed at 3-4 weeks. PROJECTED ACCRUAL: A total of 250 patients will be accrued for this study. (Phase I closed to accrual effective 07/24/2001.) |
||||
Study Phase | Phase II | ||||
Study Type † | Interventional | ||||
Study Design † | Treatment, Open Label | ||||
Primary Outcome Measure † | Clinical tumor regression [ Designated as safety issue: No ] | ||||
Secondary Outcome Measure † | Safety [ Designated as safety issue: Yes ] Survival [ Designated as safety issue: No ] Long-term immune status [ Designated as safety issue: No ] Clinical response [ Designated as safety issue: No ] Impact of administering infused cells without filgrastim (G-CSF) [ Designated as safety issue: No ] |
||||
Condition † | Melanoma (Skin) | ||||
Intervention † | Drug: aldesleukin Drug: cyclophosphamide Drug: fludarabine phosphate |
||||
MEDLINE PMIDs | 12242449 | ||||
Links | Clinical trial summary from the National Cancer Institute's PDQ® database  Featured trial article  |
||||
Recruitment Information Fields | |||||
Recruitment Status † | Recruiting | ||||
Enrollment † | 250 | ||||
Start Date † | September 1999 | ||||
Completion Date | |||||
Eligibility Criteria † | DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS: Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Pulmonary
Other
PRIOR CONCURRENT THERAPY: Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
|
||||
Gender | Both | ||||
Ages | 16 Years and older | ||||
Accepts Healthy Volunteers | No | ||||
Contacts †† | |||||
Location Countries † | United States | ||||
Administrative Information Fields | |||||
NCT ID † | NCT00019942 | ||||
Organization ID | CDR0000067331 | ||||
Secondary IDs †† | NCI-99-C-0158, NCI-T99-0078 | ||||
Study Sponsor † | National Cancer Institute (NCI) | ||||
Collaborators †† | |||||
Investigators † |
|
||||
Information Provided By | National Cancer Institute (NCI) | ||||
Verification Date | November 2008 | ||||
First Received Date † | July 11, 2001 | ||||
Last Updated Date | December 11, 2008 |